InTouch Newsletter Issue 4

Congresses and Events

Three-year Results from the EVOLVE II Randomized Trial presented at ACC

EVOLVE II clinical trial, outstanding Safety and Performance EVOLVE II clinical trial, outstanding Safety and Performance

Three-year follow-up from EVOLVE II trial presented by Dr. Dean Kereiakes supports longer-term safety and efficacy of the novel abluminal bioabsorbable polymer SYNERGY™ everolimus-eluting stent in a broad range of patients undergoing PCI.

Learn more

Synergy™ BP Stent Launches 48mm Length

Heal long lesions with confidence Heal long lesions with confidence

Long lesions represent a complex lesion subset that is associated with increased safety related events, reduced efficacy and increased procedure time. SYNERGY™ BP Stent was designed for quality healing and safety over time and with the addition of a 48mm length it has a complete size matrix to address these complex lesions.

Learn more

Boston Scientific announces Agreement to acquire Symetis

ACURATE TA™ ACURATE TA™

Boston Scientific announced a definitive agreement to acquire Symetis SA. The Symetis portfolio includes the ACURATE TA™ and ACURATE neo/TF valve* systems for use in the treatment of high-risk patients suffering from severe and symptomatic aortic valve stenosis.

Learn more

Educational Corner

EuroPCR LIVE case: Rotablation of LAD

EuroPCR LIVE case: Rotablation of LAD. St. Thomas’ Hospital (London) EuroPCR LIVE case: Rotablation of LAD. St. Thomas’ Hospital (London)

Invasive physiological assessment can be used to guide revascularization of residual disease after PCI. From St. Thomas’ Hospital (London), a live demonstration of an optimal complete revascularization after primary PCI in patients with multivessel disease. Learn more about rotablation of LAD.

Learn more

InCathlab Live Case: Right Coronary Artery CTO. Antegrade Recanalization

InCathlab Live Case: Right Coronary Artery CTO InCathlab Live Case: Right Coronary Artery CTO

An innovative operation, the Antegrade Recanalization with Hybrid Approach, conducted with a live demonstration from London Chest Hospital by Dr. Elliot Smith and Dr. Simon Walsh.

Learn more

GUIDEZILLA™: back-up support for calcified, complex and tortuous anatomy

Brian D. Arcement MD Gulf Coast Hospital Fort Myers, Florida, USA Brian D. Arcement MD Gulf Coast Hospital Fort Myers, Florida, USA

This case illustrates the need of GUIDEZILLA™ Guide Extension Catheter as a transradial back-up support for calcified, complex and tortuous anatomy.

“There is no way I would get two stents around two 90 degree turns without the support of the GUIDEZILLA™”, says Dr. Brian D. Arcement.

Learn more

Clinical Studies

Early Discontinuation of Dual-Antiplatelet Therapy with SYNERGY™ Stents in High-Risk Patients Undergoing Complex PCI

Early Discontinuation of Dual-Antiplatelet Therapy with SYNERGY™ Stents in High-Risk Patients Undergoing Complex PCI Early Discontinuation of Dual-Antiplatelet Therapy with SYNERGY™ Stents in High-Risk Patients Undergoing Complex PCI

As more elderly and co-morbid patients require percutaneous revascularization, 1 year of dual-antiplatelet therapy (DAPT) becomes concerning. SYNERGY™ stents allow for early cessation of DAPT.

Learn more

Rotational atherectomy: You will never regret using it!

Dr. T.  Strisciuglio and Dr. E.  Barbato: Rotational atherectomy: You will never regret using it! Dr. T.  Strisciuglio and Dr. E.  Barbato: Rotational atherectomy: You will never regret using it!

The contemporary RA technique aims to smoothen the lumen and disconnect the calcified coronary ring, thus leaving the way clear for further balloon dilatation and stent implantation. Dr. Teresa Strisciuglio and Dr. Emanuele Barbato illustrate the advantages deriving from the contemporary rotational atherectomy technique.

Learn more

Synergy™ Stent: ST Rates from the Academic Research Consortium

Table: Synergy™ Stent: ST Rates from the Academic Research Consortium Table: Synergy™ Stent: ST Rates from the Academic Research Consortium

According to the Academic Research Consortium, SYNERGY™ has demonstrated very low stent thrombosis rates across multiple clinical trials. Data in the table below show that Synergy™ Stent, with its abluminal and bioabsorbable polymer has reported consistently low sub-acute, late & very late ST in 18,000 patients across 9 studies.

Learn more

Top